Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00167999 |
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Condition | Intervention | Phase |
---|---|---|
Gram-Positive Bacterial Infections Escherichia Coli Infections Klebsiella Infections |
Drug: piperacillin-tazobactam |
Phase IV |
Study Type: | Observational |
Study Design: | Natural History, Longitudinal, Case Control, Prospective Study |
Official Title: | Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units. |
Ages Eligible for Study: | 15 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 0910X-101676 |
Study First Received: | September 11, 2005 |
Last Updated: | March 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00167999 |
Health Authority: | Korea: Food and Drug Administration |
Bacterial Infections |
Bacterial Infections Klebsiella Gram-Positive Bacterial Infections Penicillanic Acid Enterobacteriaceae Infections Escherichia coli Infections |
Klebsiella Infections Tazobactam Piperacillin Piperacillin-tazobactam combination product Pneumonia Gram-Negative Bacterial Infections |
Anti-Infective Agents Anti-Bacterial Agents Communicable Diseases Molecular Mechanisms of Pharmacological Action |
Therapeutic Uses Enzyme Inhibitors Infection Pharmacologic Actions |